Working… Menu

The Effects of Celecoxib on Bone Ingrowth

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00585156
Recruitment Status : Terminated (New clinical finding with Celebrex and cardiac concerns.)
First Posted : January 3, 2008
Last Update Posted : March 14, 2016
Information provided by (Responsible Party):
University of Utah

Brief Summary:
The purpose of this study is to evaluate the effect of Celebrex on bone growth into porous coated implants, following postoperative total knee arthroplasty administration of Celebrex for pain relief.

Condition or disease Intervention/treatment Phase
Bone Ingrowth Pain Drug: Celecoxib Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Intervention Model: Single Group Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effects of Celecoxib on Bone Ingrowth in Porous Coated Titanium Ceramic Implants in Humans
Study Start Date : June 2008
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Celecoxib

Arm Intervention/treatment
Experimental: Arm #1
Celebrex treatment group
Drug: Celecoxib
Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
Other Name: Celebrex

Primary Outcome Measures :
  1. Bone Ingrowth [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. Pain Score [ Time Frame: 10 days postoperative ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 95 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male VA bilateral TKA patients 18 years or older with primary OA diagnosis

Exclusion Criteria:

  • Patients with osteoporosis, hypersensitivity to Celebrex, allergy to tetracycline, Sulfonamides, patient with asthma, urticaria, or allergic-type reactions to aspirin or NSAIDs.
  • Patients who have had CABG.
  • Patients with a history of peptic ulcer disease, duodenal ulcers.
  • Female patients and patients diagnosed with unstable hypertension or hypotensive, with serum creative levels above 1.8-2.0 or diagnosed with severe renal disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00585156

Layout table for location information
United States, Utah
Veteran Affairs (VA) Medical Center
Salt Lake City, Utah, United States, 84148
Sponsors and Collaborators
University of Utah
Layout table for investigator information
Principal Investigator: Roy Bloebaum, Ph.D. Research Professor, Orthopedic Surgery

Layout table for additonal information
Responsible Party: University of Utah Identifier: NCT00585156     History of Changes
Other Study ID Numbers: IIR#2005-0300
First Posted: January 3, 2008    Key Record Dates
Last Update Posted: March 14, 2016
Last Verified: March 2016
Keywords provided by University of Utah:
Celebrex, Bone Ingrowth, Pain relief
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action